Cell Therapy

Arcellx and Gilead's New Therapy Shows Promise for Multiple Myeloma
Research & Development Arcellx and Gilead's New Therapy Shows Promise for Multiple Myeloma

The ongoing search for better and safer treatments for multiple myeloma, a type of blood cancer, has taken a significant step forward with the development of a new cell therapy by Arcellx and Gilead Sciences. The pioneering approach demonstrated a substantial reduction or total eradication of

Pluri and Bar-Ilan Partner to Innovate Solid Tumor Cell Therapies
Research & Development Pluri and Bar-Ilan Partner to Innovate Solid Tumor Cell Therapies

Pluri Inc., a forward-thinking biotechnology firm, has recently announced a groundbreaking collaborative project with Bar-Ilan University’s Research and Development Company (BIRAD). This innovative endeavor aims to develop cutting-edge allogeneic cell therapies specifically targeting solid tumors,

Neurogene Secures $200 Million Funding Ahead of Key Rett Syndrome Data
Research & Development Neurogene Secures $200 Million Funding Ahead of Key Rett Syndrome Data

Neurogene, a trailblazer in the gene therapy field concentrating on rare neurological diseases, has successfully clinched $200 million through a private funding deal designed to extend its financial runway until late 2027. This financing structure, recognized as a PIPE financing (Private Investment

Can Plasma Protein Therapy Revolutionize Modern Medicine by 2030?
Management & Regulatory Can Plasma Protein Therapy Revolutionize Modern Medicine by 2030?

The Global Plasma Protein Therapeutics Market is on a significant growth trajectory, projected to reach approximately USD 40 billion by 2030. This expansion is driven by the indispensable role that plasma protein therapies play in treating a wide array of medical conditions, such as hemophilia,

How Will Novartis and Monte Rosa Advance MRT-6160 in Immune Therapies?
Research & Development How Will Novartis and Monte Rosa Advance MRT-6160 in Immune Therapies?

Monte Rosa Therapeutics, Inc., and Novartis have recently entered into an exclusive global development and commercialization license agreement that aims to advance molecular glue degraders (MGDs), with a particular focus on MRT-6160. This agreement grants Novartis the worldwide rights to develop,

How Is Switzerland Leading Innovation in the Biotech Industry?
Biotech & Bioprocessing How Is Switzerland Leading Innovation in the Biotech Industry?

Switzerland has established itself as a global leader in the biotech industry, making significant advancements in areas such as cancer treatment, immunotherapy, gene and cell therapy, and more. With a strong focus on personalized and precision medicine, the Swiss biotech sector thrives on

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later